logo
France: Multi-year Budget Plan Supports Fiscal Outlook but Great Uncertainty Remains

France: Multi-year Budget Plan Supports Fiscal Outlook but Great Uncertainty Remains

Yahoo2 days ago
The French government affirmed its commitment to stabilise the public debt trajectory by 2029 through savings and supply-side reforms, following two years of budgetary slippage that resulted in a budget deficit of 5.8% of GDP in 2024, the highest in the euro area.
Under Prime Minister François Bayrou's EUR 44bn of measures for the 2026 Budget (equivalent to around 1.5% of GDP), the government plans to keep public spending unchanged relative to 2025 levels, excluding military expenditure and interest payments. According to the plan, this will be achieved primarily through a nominal freeze on social benefits (including pensions) and income tax bands, alongside local government savings.
If fully implemented – which is unlikely in the view of Scope Ratings (Scope) – the government's plan would reduce the budget deficit from an expected 5.4% in 2025 to 4.6% in 2026 and 2.8% in 2029. Instead, Scope expects a much more constrained and gradual fiscal consolidation path with the budget deficit still at 5% of GDP in 2027 and 4% in 2030 (Figure 1).
This is because the impact of the savings plan on the headline deficit will be partially offset by the steady increase in net interest payments, from less than 4% of government revenue in 2024 to more than 6% by 2030. So, while the primary deficit is expected to return to its pre-Covid level of less than 1% of GDP by 2030, the headline deficit will remain elevated around 4% of GDP.
Figure 1. Large primary deficits, rising interest payments weigh on the fiscal outlook
% of GDP
Savings Challenged by Economic Slowdown, Parliamentary Fragmentation and Rising Defence Expenditure
The prime minister's measures to support domestic production include the elimination of two bank holidays, the reduction of red tape for businesses and greater labour market flexibility through upcoming negotiations with social partners on the unemployment benefits system.
However, the introduction of ambitious structural reforms to support GDP growth, estimated at around 1% annually, appears unlikely in the near term. Modest economic momentum will weigh on the social acceptability of economic and budgetary reforms. Scope projects real GDP growth of 0.8% on average in 2025-26, after 1.1% in 2024, amid external headwinds including the United States's trade policies.
In addition, the lack of a parliamentary majority since the 2022 legislative elections, the fragmented political landscape and heightened political polarisation following the 2024 dissolution of the National Assembly raise further uncertainties about the government's ability to implement its saving plans for 2026.
Parliamentary discussions are expected to be challenged by difficult budgetary trade-offs to compensate for higher defence expenditures, projected to reach EUR 64bn in 2027 or about 2% of GDP. Discussions around the 2023 pension reform following this year's negotiations with social partners could also complicate the parliamentary debate.
The need to strike a political compromise on the proposed economic and budgetary reforms will likely lead the government to water down some of its measures to appease political opposition, at the risk of missing next year's deficit targets.
Conversely, relying on Article 49.3 of the Constitution to pass the 2026 Budget without a parliamentary vote will raise the risk of renewed political instability, following the collapse of the former government in December 2024. A successful no-confidence vote against the prime minister and/or early elections would undermine near-term fiscal consolidation.
Political Hurdles Compound Uncertainties Around the Government's Saving Plan
Upcoming elections – municipal elections in March 2026 and presidential elections in April-May 2027 – raise further uncertainties about budgetary efforts over the medium term.
Reducing the deficit to below 3% of GDP by 2029 would require a savings plan of more than EUR 100bn, according to the French Court of Auditors. This is unlikely, given the uncertainty surrounding the policy agenda after the 2027 presidential elections.
Figure 2. Large budget deficits, uncertain consolidation plan weigh on France's debt trajectory
% of GDP
Balancing the government's savings plan and the uncertainties around its implementation over the coming years, Scope believes general government debt to GDP will increase from about 113% in 2024 to 122% in 2030 (Figure 2). This would be one of the largest public debt increases among highly indebted developed countries, including Belgium, the United Kingdom and the United States.
For a look at all of today's economic events, check out our economic calendar.
Thomas Gillet is a Director in Sovereign and Public Sector ratings at Scope Ratings. Brian Marly, Senior Analyst in sovereign ratings at Scope, contributed to drafting this article.
This article was originally posted on FX Empire
More From FXEMPIRE:
Navigating China's Economic Challenges: A Q&A with Scope Ratings' Dennis Shen
Buy Like Big Money: Carpenter Technology Soars
Buy Like Big Money: Bentley Systems Lifting Off
SoFi Shares See Huge Bullish Signal, Could Rise More
Identify Superstar Stocks Like DoorDash Before the Crowd
Identify Superstar Stocks Like American Superconductor Early
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NatWest To Overhaul Digital Banking With AWS, Accenture
NatWest To Overhaul Digital Banking With AWS, Accenture

Yahoo

time12 minutes ago

  • Yahoo

NatWest To Overhaul Digital Banking With AWS, Accenture

NatWest Group (NYSE:NWG) on Wednesday unveiled a five-year strategic partnership with Amazon Web Services Inc. (NASDAQ:AMZN) and Accenture Plc (NYSE:ACN) to overhaul its digital infrastructure and elevate customer experiences through cloud computing, AI, and advanced data analytics. The initiative targets NatWest's 20 million customers, promising smarter, more responsive services driven by enhanced data capabilities and automation. Employees will also benefit from access to modern AI tools designed to simplify internal processes and improve customer interactions. Paul Thwaite, CEO of NatWest, said the collaboration supports the bank's ambition to evolve into a more agile and data-led organization. Thwaite noted that this effort will help the bank deliver tailored solutions more efficiently, with customer expectations rapidly Sweet, Chair and CEO of Accenture, described the project as a reinvention of NatWest's approach to banking, using data to create seamless and personalized financial journeys. She emphasized the role of AI in enhancing productivity and generating value. Matt Garman, CEO of AWS, highlighted the platform's ability to provide the agility and reliability NatWest needs to deepen customer relationships while remaining secure and scalable. He pointed to the bank's AI-enabled systems as a model for innovation in the financial sector. Key components of the plan include consolidating multiple data sources into one AI-powered platform, simplifying customer onboarding through digital tools, and enhancing fraud prevention and regulatory reporting. The integration aims to streamline operations and support faster decision-making. The announcement coincides with Accenture's efforts to broaden its AI footprint in Southeast Asia, including a recent acquisition in Malaysia that strengthens its data consulting services. Related ETFs: Vanguard Information Technology ETF (NYSE:VGT), Global X Artificial Intelligence & Technology ETF (NASDAQ:AIQ). Price Action: At last check Wednesday, NWG shares were trading higher by 0.22% to $13.62 premarket. ACN closed 1.60% higher at $286.96 on Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? (AMZN): Free Stock Analysis Report ACCENTURE (ACN): Free Stock Analysis Report This article NatWest To Overhaul Digital Banking With AWS, Accenture originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Yahoo

time12 minutes ago

  • Yahoo

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) ('Waldencast'), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions. 'We are excited to further diversify Obagi Medical's portfolio of medical-grade skincare with consumer centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha® ChIQ™ and MagIQ™ lines of injectable HA gels,' said Michel Brousset, Co-Founder and CEO of Waldencast. 'Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.' Obagi Medical's philosophy advocates for a holistic, science-driven approach where potent skincare and professional procedures work in tandem to achieve and maintain optimal skin health and a youthful appearance. These injectable products will play a pivotal role in the evolution of Obagi Medical into an end-to-end, synergistic solution that integrates medical-grade skincare with aesthetic treatments to deliver enhanced outcomes, prolonged results, and greater patient satisfaction. Beyond the two current offerings, the Novaestiq transaction provides access to a future pipeline of novel injectables in North America. Saypha®,2 currently undergoing U.S. Food and Drug Administration (FDA) approval, is recognized globally as a proven, safe and efficacious HA injectable with high levels of patient satisfaction. The new Obagi Medical injectable portfolio is supported by an industry-leading clinical program that reflects the brand's commitment to science-backed innovation. Core pivotal studies are more than twice the size of typical nasolabial fold (NLF) and midface trials and include the highest representation of Fitzpatrick Skin Types I, V, and VI – underscoring Obagi Medical's mission to provide effective solutions for all skin types and tones. Saypha® is distinguished by its proprietary technology delivering advanced HA treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. This technology powers a portfolio of clinically proven products that lead in multiple performance categories including high HA content at injection, ideal gel distribution, and consistent injection force and swelling behavior. Saypha®, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced. This global reach and deep market insight allow for the delivery of trusted, personalized care to patients and professionals worldwide. 'We believe that great results start with great skincare and are perfected with great after care,' said Dr. Suzan Obagi, Chief Medical Director at Obagi Medical. 'By combining Obagi Medical skincare with injectable procedures under the guidance of a qualified professional, patients can achieve more significant, longer-lasting, and natural-looking results. This acquisition also allows our professionals to offer patients more personalized, higher quality and safer products that their customers are looking for.' Obagi Medical's vision is to become the #1 Dermatological Mega Brand uniquely serving all the needs of physicians, patients and consumers globally. It is already the fastest-growing U.S. professional-skincare brand among the top ten in its category.3 This momentum is powered by a three-pronged strategy: anchoring products in dermatological science, introducing breakthrough innovations, and expanding its global reach. Brousset added, 'We are thrilled to introduce this new offering that will strengthen Obagi Medical's market position, drive innovation, and create new growth opportunities in our fast-evolving industry. We see an accelerating global convergence of health, beauty, and aesthetics – an intersection where Obagi Medical is uniquely positioned to lead. We also plan to leverage this acquisition to expand Obagi Medical's footprint.' Transaction DetailsUnder the terms of the definitive agreement relating to the transaction, Waldencast has agreed to acquire Novaestiq in exchange for (1) certain amount of cash payable at closing, (2) certain additional ongoing royalties based on net sales of Saypha® products, and (3) the contingent issuance of Waldencast class A shares (equal to approximately 7% of Waldencast's fully diluted class A shares), based on the receipt of FDA approval relating to the Saypha® products (triggering the issuance of 3,273,000 Waldencast class A shares) and the achievement of cumulative net revenue thresholds of (a) $100 million (triggering the issuance of an additional 3,273,000 Waldencast class A shares) and (b) $200 million (triggering the further issuance of 3,273,000 Waldencast class A shares), respectively, reflecting meaningful long-term commercial targets, with (a) and (b) being earnable until June 20, 2031. The details of the transaction will be summarized in more detail in a Form 6-K that Waldencast will file with the U.S. Securities and Exchange Commission (the 'SEC') following this press release. About WaldencastFounded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: . About Obagi MedicalObagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,3 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand's website, 1In preparing for this transaction, Waldencast engaged management consulting services from a reputed global consulting firm. 2Saypha® products are not approved medical devices, and each product has a premarket approval (PMA) application under review by the FDA. 3Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline's 2024 Global Professional Skin Care Series (China, Europe and the U.S.). AdvisorsHolland & Knight LLP is serving as Waldencast's legal advisor, with support from Skadden, Arps, Slate, Meagher & Flom LLP. Experium Capital Advisers is serving as Waldencast's financial advisor. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the intended benefits of the transaction with Novaestiq, the ability to obtain FDA approval for Saypha®, the contingent issuance of Waldencast class A shares, and the growth strategies of Waldencast, including Obagi Medical and Novaestiq. These forward-looking statements generally are identified by the words 'estimates,' 'projects,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose,' 'target,' 'goal,' 'objective,' 'outlook' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, Obagi Medical and Novaestiq that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to recognize the anticipated benefits of the transaction; (ii) the inability to obtain FDA approval for one or both of the Saypha® products; (iii) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (iv) the overall economic and market conditions, sales forecasts and other information about Waldencast's possible or assumed future results of operations or our performance; (v) changes in general economic conditions; (vi) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations; (vii) that the price of Waldencast's securities may be volatile due to a variety of factors, including Waldencast's, Obagi Medical's or Novaestiq's inability to implement their business plans; and (viii) the ability to implement Waldencast's strategic initiatives and continue to innovate Obagi Medical's existing products and anticipate and respond to market trends and changes in consumer preferences. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Waldencast's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025, or in other documents that may be filed or furnished by Waldencast from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Waldencast assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts InvestorsICRinvestors@ MediaICRwaldencast@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Buyout firms circle escrow arm of listed cybersecurity group NCC
Buyout firms circle escrow arm of listed cybersecurity group NCC

Yahoo

time12 minutes ago

  • Yahoo

Buyout firms circle escrow arm of listed cybersecurity group NCC

The private equity group which owns compliance and energy services group Sureserve is among the bidders circling a division of NCC Group, the London-listed cybersecurity company. Sky News understands that Cap10 has expressed an interest in buying Escode, which specialises in software escrow and verification services. City sources said that Platinum Equity, a US-based buyout firm, was also among Escode's suitors. Interest from earlier bidders, including Bridgepoint and Montagu Private Equity, is said to have waned. A deal could cost any buyer in the region of £300m. Last week, Sky News revealed that NCC Group had kicked off a strategic review of its main cybersecurity operations which could also lead to a sale. The Escode process is being handled by bankers at Lazard, with the cybersecurity division's review overseen by Rothschild. NCC has confirmed both sets of discussions to investors, although their outcome remains unclear. The group employs about 2,200 people across Europe, North America and Asia-Pacific. Shares in NCC Group were trading on Wednesday morning at about 146.8p, giving the company a market valuation of roughly £467m. Cap10 and NCC declined to comment, while Platinum could not be reached for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store